Find Clinical Trials

Search thousands of clinical trials by condition, location, and eligibility criteria

0
Total Trials
0
Trials Recruiting
0
Conditions Covered
0
Locations Worldwide
0
Sponsors
Clinical trial guides

Browse trials by condition

View all guides

Browse by location

Showing 12 of 4281 trials
Conditions Breast Cancer
Phase PHASE1
Enrollment 42
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This study will evaluate the safety, tolerability and efficacy of anlotinib and trastuzumab deruxtecan in human epidermal growth factor receptor 2 (HER2)-low unresectable and/or metastatic breast cancer who had received ≤1 line of prior chemotherapy.

Design

Study type: Interventional Phases: Phase1 Allocation: Intervention model: Sequential Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: Anlotinib — Anlotinib is a new, orally administered tyrosine kinase inhibitor that targets vascular endothelial growth factor receptor (VEGFR), fibroblast growth factor receptor (FGFR), platelet-derived growth factor receptors (PDGFR), and c-kit.
  • Drug: Trastuzumab deruxtecan — Trastuzumab deruxtecan is an antibody-drug conjugate composed of an anti-HER2 (human epidermal growth factor receptor 2) antibody, a cleavable tetrapeptide-based linker, and a cytotoxic topoisomerase I inhibitor.

Primary Outcomes

  • Determination of the RP2D of anlotinib in combination with trastuzumab deruxtecan (up to 1 year)
  • Objective Response Rate (ORR) (Up to approximately 3 years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE1
Status: Recruiting
Start Date: 2024-07-31
Completion: 2027-06-30
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 42 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Fudan University
Contact Information
Study Contact:
Jian Zhang, MD,PhD
+8664175590
syner2000@163.com
Jian Zhang
Interventions
  • Drug: Anlotinib — Anlotinib is a new, orally administered tyrosine kinase inhibitor that targets vascular endothelial growth factor receptor (VEGFR), fibroblast growth factor receptor (FGFR), platelet-derived growth factor receptors (PDGFR), and c-kit.
  • Drug: Trastuzumab deruxtecan — Trastuzumab deruxtecan is an antibody-drug conjugate composed of an anti-HER2 (human epidermal growth factor receptor 2) antibody, a cleavable tetrapeptide-based linker, and a cytotoxic topoisomerase I inhibitor.
Study Locations (1 sites)
Jian Zhang, Shanghai, Shanghai Municipality 200433 China
Eligibility Criteria
Inclusion Criteria: * 1\. Age 18 - 75 years; ECOG PS 0 or 1. 2. Pathologically documented breast cancer that: 1. Is unresectable or metastatic. 2. Has a history of low HER2 expression (IHC 1+\& IHC 2+/ISH- or 0\<IHC\<1+). 3. Is HR-positive or HR-negative. 4. Has progressed on, and would no longer benefit from, endocrine therapy. 5. Has been treated with ≥1 prior lines of chemotherapy/adjuvant in the recurrent or metastatic setting. 3\. At least 1 measurable lesion per Response Evaluation Criteria in Solid Tumors version 1.1(Previously treated lesions with radiotherapy or focal therapy and no progression cannot be included as target lesion for assessment). 4\. Has protocol-defined adequate bone marrow, renal, hepatic and blood clotting functions. 5\. Male and female subjects of reproductive/childbearing potential must agree to use a highly effective form of contraception or avoid intercourse during and upon completion of the study and after the last dose for at least 6 months. Exclusion Criteria: 1. Has previously been treated with anti-angiogenic targeted small molecule therapy. 2. Prior treatment with antibody drug conjugate with a topoisomerase I inhibitor exatecan derivative. 3. Has a history of (noninfectious) ILD/pneumonitis that required steroids, has current ILD/pneumonitis, or where suspected ILD/pneumonitis cannot be ruled out by imaging at screening. 4. Has unresolved toxicities from previous anticancer therapy. 5. Has uncontrolled or significant cardiovascular disease. 6. Has any bleeding event, unhealed wounds, ulcerative or fractures. 7. Has arterial or venous thromboembolic events occurred within 6 months. 8. Has spinal cord compression or clinically active central nervous system metastases. 9. Has any other condition that per protocol or in the opinion of the investigator is inappropriate for the study.
Conditions Triple-negative Breast Cancer
Phase NA
Enrollment 29
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

To evaluate the clinical efficacy and safety of oral all-trans retinoic acid in combination with toripalimab in patients with locally advanced, recurrent, or metastatic triple-negative breast cancer who had failed second-line and subsequent therapy.

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: ATRA — ATRA is the main active metabolite of vitamin A. Studies have shown that ATRA can also reduce the number of MDSC in solid tumor patients, promote their differentiation and maturation, remove the immunosuppressive ability of MDSC, improve the tumor immune microenvironment, and thus improve the tumor treatment efficacy.
  • Drug: Toripalimab — Toripalimab is a fully human monoclonal antibody injection against PD-1 receptor. The NMPA has accepted the application of Toripalimab for a new indication for the treatment of initial metastatic or relapsed metastatic TNBC with PD-L1 positive (CPS≥1).

Primary Outcomes

  • Objective Response Rate (ORR) (up to 2 years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-10-10
Completion: 2026-04-30
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 29 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: First Affiliated Hospital of Zhejiang University
Collaborators: Shanghai Longfine Biotechnology Co., Ltd., TopAlliance
Principal Investigators:
  • Xiaochen Zhang, MD (PRINCIPAL_INVESTIGATOR) - First Affiliated Hospital of Zhejiang University
Contact Information
Study Contact:
Jian Liu, MS
+86-0571-87236537
lindaliu87@zju.edu.cn
Meihua Lin, MS
mhlin2015@zju.edu.cn
Meihua Lin, MS
The first affiliated hospital, Zhejiang University School of Medicine
Interventions
  • Drug: ATRA — ATRA is the main active metabolite of vitamin A. Studies have shown that ATRA can also reduce the number of MDSC in solid tumor patients, promote their differentiation and maturation, remove the immunosuppressive ability of MDSC, improve the tumor immune microenvironment, and thus improve the tumor treatment efficacy.
  • Drug: Toripalimab — Toripalimab is a fully human monoclonal antibody injection against PD-1 receptor. The NMPA has accepted the application of Toripalimab for a new indication for the treatment of initial metastatic or relapsed metastatic TNBC with PD-L1 positive (CPS≥1).
Study Locations (1 sites)
The first affiliated hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang Province, P.R. China 310003 China
Eligibility Criteria
Inclusion Criteria: 1. Age ≥18 years at the time of signing the informed consent form; 2. Pathologically confirmed as triple-negative breast cancer based on recent biopsy or other pathological specimens, with histological and/or cytological diagnosis; 3. Patients with unresectable locally advanced or metastatic triple-negative breast cancer who have failed at least second-line standard treatment regimens; 4. According to RECIST 1.1, at least one measurable lesion is required. Patients with only skin lesions or bone lesions are not eligible for inclusion; 5. Adequate organ and bone marrow function (not received blood transfusions, recombinant human platelet growth factor, or colony-stimulating factor treatment in the 2 weeks before screening); 6. The subject voluntarily agrees to participate in this study, signs the informed consent form, and is able to comply with the visits and related procedures specified in the protocol. Exclusion Criteria: 1. Known symptomatic or uncontrolled brain metastasis or other central nervous system (CNS) metastases; 2. Patients with other malignant tumors, excluding those with cured basal cell or squamous cell skin carcinoma or in situ cervical cancer. Patients with other malignant tumors must have a disease-free interval of at least 5 years; 3. Any severe and/or uncontrolled concurrent illness that hinders the patient's participation in the study; 4. History of immunodeficiency, autoimmune diseases, the need for immunosuppressive therapy (daily dose \&gt;10 mg of prednisone or equivalent), or a history of chronic infections; 5. History of deep vein thrombosis or pulmonary embolism; 6. Severe osteoporosis or patients with bone metastases; 7. Participants who, within the first 4 weeks before the initiation of the study treatment or during the 5 half-lives of any drugs used in the pre-study period (whichever is shorter), have received any chemotherapy, immunotherapy, biologic therapy, or participated in other drug clinical trials, or received traditional Chinese medicine preparations for the treatment of approved anticancer indications or radiotherapy within the first 2 weeks before the initiation of the study treatment, or have undergone major surgery within the first 4 weeks before the initiation of the study treatment; 8. Patients with active hepatitis B or C; known history of human immunodeficiency virus (HIV) infection or acquired immunodeficiency syndrome (AIDS); positive syphilis antibody test; 9. History of severe drug allergies or known allergy to any component of the investigational drug as per the prescription; 10. The investigator considers the participant unsuitable for the study.
Conditions Depression, Anxiety
Phase NA
Enrollment 138
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Depression and anxiety are the most prevalent mental disorders among both the general population and young adults, and transdiagnostic treatments for these patients are mostly based on cognitive-behavioral therapy (CBT). Based on common (transdiagnostic) principles of treatment (e.g., emotional exposure), these approaches have proliferated and demonstrated their efficacy in comparison to disorder-specific treatments. Although there are a few transdiagnostic approaches for children and adolescents, it was not possible to not find anyone targeting young people. For this reason, the investigators proposed the Identity-Based Transdiagnostic Therapy (IBTT) as a new treatment modality ideally created to address the challenge of improving the outcomes of psychotherapy for young adults with anxiety and/or depression. The IBTT is a psychological treatment for emotional disorders specifically designed for the youths in terms of their attitudes to treatment (attractiveness, engagement), and highly personalized to their construal of self and others. This project will allow testing the hypothesis that a novel brief psychotherapeutic intervention, IBTT, will be more efficacious in the treatment of the anxiety and/or depression of young adults than the well-established CBT-based Unified Protocol.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Single

Interventions / Regimen

  • Behavioral: Identity-Based Transdiagnostic Therapy (IBTT) — In this study, IBTT is applied in 16, one-hour weekly sessions based on contemporary constructivist psychotherapy enhanced with the technological platform EYME-Explore Your Meanings to enable the immersive exploration of the patient's self-identity. Although it could be applied to other populations, IBTT has been designed to improve the mental health of late adolescents and young people.
  • Behavioral: Unified Protocol — In this study, the UP is applied in 16, one-hour weekly sessions based on contemporary cognitive and behavioral techniques.

Primary Outcomes

  • Depression, Anxiety and Stress Scales (DASS-21) (DASS-21 will be administered at baseline, at 16 weeks (at completion), and at three-month follow-up.)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-05-02
Completion: 2027-11-02
Eligibility
Age: 16 Years and older
Sex: ALL
Volunteers: false
Enrollment: 138 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Barcelona
Collaborators: Badalona Serveis Assistencials, Nou Barris Mental Health Center, Pere Claver Grup
Principal Investigators:
  • Guillem Feixas, PhD (PRINCIPAL_INVESTIGATOR) - University of Barcelona
Contact Information
Study Contact:
Guillem Feixas, PhD
+34933125100
gfeixas@ub.edu
Irene Alvarez, PhD
iatomas@bsa.cat
Badalona Serveis Assistencials
Giuseppina Rametti, PhD
giusi.rametti@csm9b.com
Associació Centre Higiene Mental Nou Barris
Interventions
  • Behavioral: Identity-Based Transdiagnostic Therapy (IBTT) — In this study, IBTT is applied in 16, one-hour weekly sessions based on contemporary constructivist psychotherapy enhanced with the technological platform EYME-Explore Your Meanings to enable the immersive exploration of the patient's self-identity. Although it could be applied to other populations, IBTT has been designed to improve the mental health of late adolescents and young people.
  • Behavioral: Unified Protocol — In this study, the UP is applied in 16, one-hour weekly sessions based on contemporary cognitive and behavioral techniques.
Study Locations (2 sites)
Badalona Serveis Assistencials, Badalona, 08911 Spain
Associació Centre Higiene Mental Nou Barris, Barcelona, 08042 Spain
Eligibility Criteria
Inclusion Criteria: • Participants with symptoms of depression and/or anxiety as their primary complaint. Exclusion Criteria: * Participants with post-traumatic stress, bipolar and substance use disorders, psychotic symptoms, organic brain dysfunction, marked suicidal ideation and/or intellectual disability. * Participants receiving psychological treatment, unless it is suspended at the time of inclusion in the study itself in agreement with their therapist. * Participants for whom the use of virtual reality may pose a risk, even a minor risk (epilepsia, acute otorhinolaryngological processes or recent interventions, severe cardiovascular disease, unstable hypertension, and pregnancy). * Participants with substantial visual, hearing, and cognitive deficits. * Participants who do not have enough competence to communicate in Spanish or Catalan.
Conditions Obesity, Diabetes Mellitus, Type 2
Phase Not Applicable
Enrollment 300
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

In the UK alone, obesity is a major health problem with more than one quarter of adults estimated to be obese. Obesity promotes the development of many serious diseases including diabetes, heart disease, kidney disease, and increased risk of some cancers. Patients living with obesity also suffer from significant symptoms that impact their life including shortness of breath, back pain, poor mobility, and poor mental health. Traditional methods to help lose weight include low calorie diets and increased exercise. These may be effective in the short-term, but due to powerful biological mechanisms they are hard to maintain over the long-term and most individuals are unable to achieve normal weight. This means many people may need bariatric surgery that is highly effective at lowering body weight, but it is associated with complications and not all patients will want or be able to undergo surgery. This has led to the development of many new obesity treatments that are completed with an endoscope. An endoscope is a thin flexible tube that has a camera at the end. It is inserted through the mouth and into the stomach and small bowel. There are various procedures that can be done at the time of endoscopy that have been shown to be effective with a low number of side-effects. These are still relatively new compared to more traditional treatments and only a small number of doctors can perform them within the UK. Due to these limitations, the aim of this registry is to obtain real-world information on the safety and effectiveness of these procedures across the UK. The investigators hope over time this will improve the knowledge of clinicians about treating obesity with endoscopy and support future access and funding to these treatments.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Interventions / Regimen

  • Device: Endoscopic gastric suturing — Endoscopic suturing of the stomach to reduce volume and promote weight loss with either the Apollo Overstitch or Overstitch Sx system.
  • Device: Endoscopic gastric plication — Endoscopic plication of the stomach to reduce volume and promote weight loss with either the POSE or Endomina system.
  • Device: Revisional gastroplasty — Endoscopic suturing or plication of the stomach among patients who have previously undergone gastroplasty, sleeve gastrectomy, or Roux-en-Y gastric bypass to restrict the stomach and promote weight loss
  • Device: Transoral outlet reduction endoscopy (TORe) — Reduction of the size of the gastro-jejunal anastomosis among patients who have previously undergone Roux-en-Y gastric bypass to promote weight loss. A variety of techniques may be used alone or in isolation including suturing (Apollo Overstitch), plication (POSE), argon photocoagulation, and endoscopic submucosal resection/dissection.
  • Device: Duodenal mucosal resurfacing (DMR) — Endoscopic ablation of the post-ampullary duodenal mucosal to enhance improvement in glycaemic control among patients with type 2 diabetes.
  • Device: Intragastric balloon(s) — The insertion of an intragastric implant into the stomach, which is subsequently filled with air or water to promote weight loss. Several intragastric balloons are available including Allurion, Heliosphere, Obalon, Orbera, and Spatz.

Primary Outcomes

  • Total body weight loss percentage (TBWL%) (6-months, 1-, 2-, 3-, 5-years)
  • Change in glycated haemoglobin (HbA1c; mmol/mol) (6-months, 1-, 2-, 3-, 5-years)
  • Change in the number and dose of anti-diabetic medications (6-months, 1-, 2-, 3-, 5-years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2024-02-01
Completion: 2039-02-01
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 300 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Cleveland Clinic London
Principal Investigators:
  • Rehan Haidry, MD (PRINCIPAL_INVESTIGATOR) - Cleveland Clinic London
Contact Information
Study Contact:
Benjamin Norton, MD
+442034237500
cclendoscopyresearch@ccf.org
Fiona Makia
+442034237500
cclresearch@ccf.org
Benjamin Norton, MD
cclendoscopyresearch@ccf.org
Cleveland Clinic London
Interventions
  • Device: Endoscopic gastric suturing — Endoscopic suturing of the stomach to reduce volume and promote weight loss with either the Apollo Overstitch or Overstitch Sx system.
  • Device: Endoscopic gastric plication — Endoscopic plication of the stomach to reduce volume and promote weight loss with either the POSE or Endomina system.
  • Device: Revisional gastroplasty — Endoscopic suturing or plication of the stomach among patients who have previously undergone gastroplasty, sleeve gastrectomy, or Roux-en-Y gastric bypass to restrict the stomach and promote weight loss
  • Device: Transoral outlet reduction endoscopy (TORe) — Reduction of the size of the gastro-jejunal anastomosis among patients who have previously undergone Roux-en-Y gastric bypass to promote weight loss. A variety of techniques may be used alone or in isolation including suturing (Apollo Overstitch), plication (POSE), argon photocoagulation, and endoscopic submucosal resection/dissection.
  • Device: Duodenal mucosal resurfacing (DMR) — Endoscopic ablation of the post-ampullary duodenal mucosal to enhance improvement in glycaemic control among patients with type 2 diabetes.
Study Locations (1 sites)
Cleveland Clinic London, London, SW1X 7HY United Kingdom
Eligibility Criteria
Inclusion Criteria: * Any patient undergoing a primary or revisional bariatric or metabolic endoscopic procedure. * Age ≥ 18 years old * Able to give written informed consent. Exclusion Criteria: * Any bariatric or metabolic endoscopic procedure performed outside the UK. * Any bariatric or metabolic endoscopic procedure not currently listed within the registry protocol or agreed by the steering committee. * Unable to provide written informed consent.
Conditions Breast Cancer
Phase Not Applicable
Enrollment 1200
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This study aims to conduct whole genome sequencing in breast cancer patients to elucidate individual genetic characteristics and their correlation with breast cancer subtypes. The primary objective is to establish new treatment guidelines aligned with the paradigm shift in precision medicine. The study will include both prospective and retrospective cohorts totaling 1200 participants. Prospective participants must provide consent and be eligible for tissue collection, while retrospective participants must have histologically confirmed breast cancer and available tissue samples from Samsung Medical Center Biobank. The study period spans 3 years for subject enrollment and 5 years for follow-up observations, with an expected completion date of December 31, 2030.

Design

Study type: Observational Observational model: Cohort Time perspective: Other

Interventions / Regimen

  • Other: no intervention needed — no intervention needed

Primary Outcomes

  • Establishing individual genetic characteristics of breast cancer patients through WGS (December.31.2030)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2022-08-02
Completion: 2030-12-31
Eligibility
Age: 19 Years and older
Sex: ALL
Volunteers: Not specified
Enrollment: 1200 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Inocras Korea Inc.
Principal Investigators:
  • JeongSeok Lee (STUDY_CHAIR) - Inocras Korea Inc.
Contact Information
Study Contact:
JeongSeok Lee, MD
82-2-587-0109
jslee@inocras.com
HyunJung Lee
82-2-587-0109
hjlee@inocras.com
Yeon Hee Park, MD
Samsung Medical Center
Interventions
  • Other: no intervention needed — no intervention needed
Study Locations (1 sites)
Samsung Medical Center, Seoul, South Korea
Eligibility Criteria
\[Prospective study\] Inclusion Criteria: * Patients who have consented to both the patient consent form and the consent for the use of human-derived materials. * Patients who are aged 19 years or older at the time of signing the consent form. * Patients capable of providing written consent to participate voluntarily in the study. * Patients eligible for tissue examination and surgical removal to facilitate sample collection. * Patients histologically confirmed with breast cancer or undergoing tissue examination for pathological confirmation due to imaging findings suggestive of breast cancer. Exclusion Criteria: * Patients who do not understand or refuse to consent in writing. * Patients for whom obtaining sufficient samples is challenging. * Patients who refuse genetic testing. \[Retrospective study\] Inclusion Criteria: * Patients histologically confirmed with breast cancer. * Patients for whom breast cancer tissues collected between 2012 and 2023 are stored in the Samsung Seoul Hospital Biobank and available for distribution. Exclusion Criteria: \- Patients for whom sufficient tissue for analysis is not adequately stored.
Conditions Breast Neoplasms
Phase PHASE3
Enrollment 1200
Locations 259 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The purpose of this study is to compare sacituzumab tirumotecan as a single agent, and in combination with pembrolizumab, versus Treatment of Physician's Choice (TPC) in participants with hormone receptor positive/human epidermal growth factor receptor-2 negative (HR+/HER2-) unresectable locally advanced, or metastatic, breast cancer. The primary hypotheses are that sacituzumab tirumotecan as a single agent and sacituzumab tirumotecan plus pembrolizumab are superior to TPC with respect to progression-free survival (PFS) per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) by blinded independent central review (BICR) in all participants.

Design

Study type: Interventional Phases: Phase3 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: Sacituzumab tirumotecan — IV infusion
  • Biological: Pembrolizumab — IV infusion
  • Drug: Paclitaxel — IV infusion
  • Drug: Nab-paclitaxel — IV infusion
  • Drug: Capecitabine — oral tablet
  • Drug: Liposomal doxorubicin — IV infusion

Primary Outcomes

  • Progression-Free Survival (PFS) ( sacituzumab tirumotecan versus treatment of physician's choice [TPC]; pembrolizumab + sacituzumab tirumotecan versus TPC) (Up to ~40 months)
  • PFS (Sacituzumab tirumotecan + pembrolizumab versus TPC) (Up to ~40 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE3
Status: Recruiting
Start Date: 2024-04-14
Completion: 2031-04-12
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 1200 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Merck Sharp & Dohme LLC
Principal Investigators:
  • Medical Director (STUDY_DIRECTOR) - Merck Sharp & Dohme LLC
Contact Information
Study Contact:
Toll Free Number
1-888-577-8839
Trialsites@msd.com
Study Coordinator
480-821-2838
Ironwood Cancer & Research Centers ( Site 0066)
Study Coordinator
480-256-6444
Banner MD Anderson Cancer Center-Oncology ( Site 0004)
Interventions
  • Drug: Sacituzumab tirumotecan — IV infusion
  • Biological: Pembrolizumab — IV infusion
  • Drug: Paclitaxel — IV infusion
  • Drug: Nab-paclitaxel — IV infusion
  • Drug: Capecitabine — oral tablet
Study Locations (259 sites)
Ironwood Cancer & Research Centers ( Site 0066), Chandler, Arizona 85224 United States
Banner MD Anderson Cancer Center-Oncology ( Site 0004), Gilbert, Arizona 85234 United States
Providence Medical Foundation-Oncology ( Site 0020), Fullerton, California 92835 United States
Moores Cancer Center ( Site 0059), La Jolla, California 92093-0698 United States
Cancer and Blood Specialty Clinic ( Site 0001), Los Alamitos, California 90720 United States
University of Colorado Anschutz Medical Campus ( Site 0061), Aurora, Colorado 80045 United States
UCHealth Cherry Creek Medical Center ( Site 0094), Denver, Colorado 80206 United States
University of Colorado Health - Highlands Ranch Hospital ( Site 0095), Highlands Ranch, Colorado 80129 United States
Yale Cancer Center ( Site 0060), New Haven, Connecticut 06510 United States
Stamford Hospital ( Site 0049), Stamford, Connecticut 06902 United States
Eligibility Criteria
Inclusion Criteria: * Has unresectable locally advanced or metastatic centrally-confirmed hormone receptor positive (HR+)/human epidermal growth factor receptor 2 negative (HER2-) breast cancer * Has radiographic disease progression on one or more lines of endocrine therapy for unresectable locally advanced/metastatic HR+/HER2- breast cancer, with one in combination with a CDK4/6 inhibitor * Is a chemotherapy candidate * Has an eastern cooperative oncology group (ECOG) performance status of 0 to 1 assessed within 7 days before randomization * Has adequate organ function * Human immunodeficiency virus (HIV)-infected participants must have well controlled HIV on antiretroviral therapy * Participants who are Hepatitis B surface antigen (HBsAg) positive are eligible if they have received HBV antiviral therapy for at least 4 weeks, and have undetectable HBV viral load * Participants with a history of Hepatitis C virus (HCV) infection are eligible if HCV viral load is undetectable Exclusion Criteria: * Has breast cancer amenable to treatment with curative intent * Has experienced an early recurrence (\<6 months after completing adjuvant/neoadjuvant chemotherapy) and therefore is eligible to receive second-line (2L) treatment * Has symptomatic advanced/metastatic visceral spread at risk of rapidly evolving into life-threatening complications * Has received prior chemotherapy for unresectable locally advanced or metastatic breast cancer * Active autoimmune disease that has required systemic treatment in the past 2 years * History of (noninfectious) pneumonitis/interstitial lung disease that requires steroids, or has current pneumonitis/interstitial lung disease * Has an active infection requiring systemic therapy
Conditions Arm Lymphedema, Breast Cancer, Radiother...
Phase Not Applicable
Enrollment 120
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

In this observational prospective studi patients with invasive breast cancer no more than 5 cm and clinically node negative, scheduled for conservative surgery and Sentinel Node Biopsy (SNB), are enrolled in the protocol if they have 1-2 sentinel lymphnodes (SLNs) with macrometastases. SLN status will be checked on definitive sections.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Interventions / Regimen

  • Radiation: Hypofractionated radiotherapy scheme — Hypofractionated radiotherapy scheme with 2.67Gy/fraction for 15 fractions. WBRT with simultaneous integrated boost to the tumor bed

Primary Outcomes

  • Percentage of patients with arm lymphedema (1 year)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2019-04-18
Completion: 2027-12-31
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 120 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: European Institute of Oncology
Principal Investigators:
  • Maria Cristina Leonardi, MD (PRINCIPAL_INVESTIGATOR) - European Institute of Oncology
Contact Information
Study Contact:
Maria Cristina Leonardi, MD
+39 02 94372156
cristina.leonardi@ieo.it
Maria Cristina Leonardi
+39 02 94372156
European Institute of Oncology
Interventions
  • Radiation: Hypofractionated radiotherapy scheme — Hypofractionated radiotherapy scheme with 2.67Gy/fraction for 15 fractions. WBRT with simultaneous integrated boost to the tumor bed
Study Locations (1 sites)
European Institute of Oncology, Milan, Italy
Eligibility Criteria
Inclusion Criteria: 1. Histological proven invasive breast cancer 2. Breast conserving surgery with no axillary dissection 3. Tumor dimension no more then 5 cm and no more than 2 positive sentinel node 5\) Negative surgical margin (no tumor cell on ink) 6) Performance Status (PS) \<2 7) Age \>18 8) Written informed consent Exclusion Criteria: 1. Previous thoracic RT 2. Mixed connective disorders 3. Distant metastases 4. Severe lung or cardiac diseases 5. Neoadjuvant systemic therapies 6. Axillary dissection 7. No surgical axillary investigation 8. Mastectomy 9. Axillary micrometastasis or isolated tumor cell
Conditions PTSD
Phase NA
Enrollment 400
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this clinical trial is see if Cognitive Processing Therapy and STAIR Narrative Therapy work to treat posttraumatic stress disorder (PTSD) among lesbian, gay, bisexual, transgender, queer/questioning, intersex, asexual/aromantic, and all other sexual or gender minority (LGBTQIA+) adults. The main questions it aims to answer are: * Do these treatments reduce PTSD symptoms in LGBTQIA+ patients? * Do these treatments help improve quality of life and reduce depression in LGBTQIA+ patients? * Do stress from stigma and discrimination and drug/alcohol use change the impact of the treatment on PTSD symptoms? * Are LGBTQIA+ patients satisfied with these treatments? Do these treatments work differently among different groups within the LGBTQIA+ community? * Do LGBTQIA+ patients complete these treatments? Study participants will receive one of these two PTSD treatments. Participants will complete assessments before and after receiving treatment.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Single

Interventions / Regimen

  • Behavioral: Cognitive Processing Therapy — Cognitive Processing Therapy teaches cognitive restructuring skills to help clients change beliefs and process emotions related to a traumatic event or events.
  • Behavioral: STAIR Narrative Therapy — STAIR Narrative Therapy teaches coping skills (e.g., for emotional regulation, interpersonal relationships, everyday stress) and includes a narrative trauma-focused component.

Primary Outcomes

  • Change in Posttraumatic Stress Disorder (PTSD) Symptoms Measured by PTSD Checklist for DSM-5 (PCL-5) (Months 0 (baseline), 3, 6, and 12)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-08-01
Completion: 2028-06
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 400 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Stanford University
Collaborators: Patient-Centered Outcomes Research Institute, University of California, San Francisco
Principal Investigators:
  • Annesa P Flentje, PhD (PRINCIPAL_INVESTIGATOR) - Stanford University
Contact Information
Study Contact:
Annesa P Flentje, PhD
650-497-7112
lgbtqia_study@ucsf.edu
Annesa Flentje, PhD
415-502-4859
lgbtqia_study@ucsf.edu
Stanford University
Annesa Flentje, PhD
UCSF Alliance Health Project
Interventions
  • Behavioral: Cognitive Processing Therapy — Cognitive Processing Therapy teaches cognitive restructuring skills to help clients change beliefs and process emotions related to a traumatic event or events.
  • Behavioral: STAIR Narrative Therapy — STAIR Narrative Therapy teaches coping skills (e.g., for emotional regulation, interpersonal relationships, everyday stress) and includes a narrative trauma-focused component.
Study Locations (2 sites)
Stanford University, Palo Alto, California 94304 United States
UCSF Alliance Health Project, San Francisco, California 94103 United States
Eligibility Criteria
Inclusion Criteria: 1. 18 years of age or older 2. Currently live in California 3. Ability to understand study procedures and to comply with them for the entire length of the study 4. Ability to understand a written informed consent document and the willing to sign it 5. Ability to speak and read English or Spanish 6. Identify as a sexual and/or gender minority 7. Score 33 or higher on the PTSD Checklist-5 (PCL-5) 8. Interest in getting treatment for PTSD 9. Not be in another concurrent psychotherapy treatment (group or individual) for PTSD (psychotherapy treatment for non-PTSD conditions is allowed). 10. Able to attend treatment sessions in person in San Francisco or have access to a device that allows for treatment via videoconferencing. Exclusion Criteria: 1. Contraindication to any study-related procedure or assessment 2. Clinically significant impairment which interferes with ability to fully participate in the study (including symptoms of schizophrenia, schizoaffective disorder, bipolar disorder, or other disorders) 3. Active suicidal intent
Conditions Breast Cancer
Phase Not Applicable
Enrollment 1800
Locations 58 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The EXActDNA-003 study will prospectively enroll participants who are planning to undergo chemotherapy for high-risk, early breast cancer, who are willing to provide tissue and blood specimens for circulating tumor DNA (ctDNA) analysis. Participants will be followed for up to 5.5 years.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Interventions / Regimen

  • Diagnostic Test: ctDNA MRD test — Blood and tissue samples will be collected for the ctDNA MRD test

Primary Outcomes

  • Core biopsy tissue evaluability rate (3 years)
  • Distant Recurrence Free Interval (dRFI) (6 years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2024-06-07
Completion: 2030-04
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 1800 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Exact Sciences Corporation
Collaborators: NSABP Foundation Inc
Contact Information
Study Contact:
NSABP Department of Site and Study Management Department of Site and Study Management
1-800-270-3165
industry.trials@nsabp.org
Theodore Kim
Katmai Oncology Group - Anchorage
Irene Wapnir
Stanford Cancer Institute
Interventions
  • Diagnostic Test: ctDNA MRD test — Blood and tissue samples will be collected for the ctDNA MRD test
Study Locations (58 sites)
Katmai Oncology Group - Anchorage, Anchorage, Alaska 99508 United States
Stanford Cancer Institute, Palo Alto, California 94304 United States
Harbor-UCLA Medical Center - Hematology / Oncology, Torrance, California 90502 United States
Kaiser Permanente Medical Center, Vallejo, California 94589 United States
UCHealth Cancer Care - Anschutz Medical Campus - University of Colorado Cancer Center, Aurora, Colorado 80045 United States
AdventHealth East Altamonte Oncology and Hematology, Altamonte Springs, Florida 32701 United States
Mount Sinai Medical - Comprehensive Cancer Center, Miami Beach, Florida 33140 United States
Baptist Cancer Care - Plantation, Plantation, Florida 33324 United States
St. Joseph's Women's Hospital, Tampa, Florida 33607 United States
Rush Cancer Center, Chicago, Illinois 60607 United States
Eligibility Criteria
Inclusion Criteria: 1. The participant or a legally authorized representative must provide study-specific informed consent prior to study entry. 2. The participant must be ≥ 18 years of age. 3. ECOG performance status 0 or 1. 4. Histologically confirmed invasive carcinoma of the breast. 5. Planned neoadjuvant therapy which includes cytotoxic chemotherapy. 6. Tumor size ≥ 2.1 cm in greatest diameter. 7. Unifocal or multifocal cancer documented to be the same histologic clinical subtype. 8. Clinically node positive or if node negative, any one of the following: 1. TNBC or HER2+ subtype 2. HR+/HER2-negative with at least one of the following: i. High tumor grade (G3) ii. Ki67 index of 20% or higher iii. High genomic risk (Oncotype DX® (ODX) Breast Recurrence Score of \> 25, MammaPrint® High, etc.) 9. Willing and able to comply with the study requirements, which includes the collection of a total of 34 cc (2.5 Tablespoons) of blood for each research blood draw. 10. Available residual tissue from diagnostic biopsy from the breast or an involved ipsilateral lymph node for submission to create a bespoke ctDNA assay. Exclusion Criteria: 1. Definitive clinical or radiologic evidence of metastatic disease. 2. Initiated neoadjuvant therapy for current breast cancer diagnosis. 3. Synchronous diagnosis of another invasive cancer, other than this breast cancer, except for non-melanoma skin cancers. 4. Completed all therapy (including endocrine therapy) \<5 years ago for any previous invasive solid organ malignancy (with exception of non-melanoma skin cancers) including prior breast cancer. Individuals with a prior history of noninvasive (in situ) carcinomas may participate if they have received definitive treatment. 5. Completed all therapy for any previous hematologic malignancy \< 5 years ago. 6. Multicentric or contralateral invasive breast cancers. 7. Known pregnancy at time of enrollment. 8. Prior solid organ transplant. 9. Prior allogeneic hematopoietic stem cell transplant.
Conditions Chronic Obstructive Pulmonary Disease, B...
Phase NA
Enrollment 246
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Background: Some health conditions make breathing difficult and uncomfortable. When this happens every day, it is called chronic breathlessness. Over 3 million people living with heart and lung disease have chronic breathlessness in the UK. Breathlessness is very difficult for patients themselves and their families, resulting in disability and feelings of fear, distress, and isolation. Due a to lack of supportive breathlessness services many patients frequently attend hospital Accident and Emergency (A\&E) departments seeking help. Given the on-going challenges faced by the National Health Service (NHS) in the United Kingdom, such as long waiting times, staff shortages, increased demand for services because of the COVID-19 pandemic, there is an urgent need to develop new ways to support those living with chronic breathlessness. One potential solution is to offer support online, as it is estimated that in the UK, 7 out of every 10 people with chronic breathlessness are internet users. With the help of patients and NIHR funding the research team lead by Dr Charles Reilly, developed an online breathlessness supportive website called SELF-BREATHE. SELF-BREATHE provides information and self-management tools such as breathing exercises, that patients can do at home themselves. SELF-BREATHE has been tested as part of its development. SELF-BREATHE is acceptable and valued by patients. But what is unknown is whether SELF-BREATHE improves patients' breathlessness and their life? This is the question this research seeks to answer. Aims 1. To test if using SELF-BREATHE for six-weeks improves patients' breathlessness, their quality of life and whether SELF-BREATHE should be offered within the NHS 2. To see if patients opt to continue to use SELF-BREATHE after six-weeks and what benefits this may have for patients. Methods The research team are undertaking a randomised controlled trial. For this, 246 people living with chronic breathlessness will be recruited in to this study. Each person will be randomly chosen by a computer to continue with their usual care or their usual care plus access to SELF-BREATHE. All study participants will complete questionnaires at the start of the study, thereafter at seven and twelve weeks after randomisation. These questionnaires will ask patients about 1) their breathlessness and its effect on their life and 2) planned and unplanned hospital visits. At the end of the study, we will compare answers to these questionnaires between the two groups at seven and 12 weeks. This will tell if SELF-BREATHE improved patients' breathlessness and reduced their need for unplanned hospital visits e.g., A\&E attendances due to breathlessness.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Single

Interventions / Regimen

  • Other: SELF-BREATHE — SELF-BREATHE is on online supportive self - management intervention for individuals living with chronic breathlessness due to respiratory disease. SELF-BREATHE provides user with educational resources about breathlessness and self - management techniques such as breathing exercises, goal setting which aims to help with their breathlessness.

Primary Outcomes

  • Numerical Rating Scale (NRS) Worst Breathlessness (previous 24 hours)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-07-04
Completion: 2028-07
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 246 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: King's College Hospital NHS Trust
Principal Investigators:
  • Charles C Reilly, PhD,MSc,BSc (PRINCIPAL_INVESTIGATOR) - King's College Hospital NHS Foundation Trust, King's College London
Contact Information
Study Contact:
Charles C Reilly, PhD,MSc,BSc
00442032998062
charles.reilly@nhs.net
Charles C Reilly
00442032998062
charles.reilly@nhs.net
King's College Hospital NHS Foundation Trust
Interventions
  • Other: SELF-BREATHE — SELF-BREATHE is on online supportive self - management intervention for individuals living with chronic breathlessness due to respiratory disease. SELF-BREATHE provides user with educational resources about breathlessness and self - management techniques such as breathing exercises, goal setting which aims to help with their breathlessness.
Study Locations (1 sites)
King's College Hospital NHS Foundation Trust, London, MK40 4DG United Kingdom
Eligibility Criteria
Inclusion Criteria: * Adults ≥ 18 years of age * Chronic Breathlessness at rest and / or exertion * Chronic Breathlessness (CB) defined as breathlessness that persists (\>3months) despite pharmacological treatment of the underlying disease including, but not limited to; cancer, chronic obstructive pulmonary disease (COPD), interstitial lung disease (ILD), bronchiectasis, chronic fibrotic lung disease following SARS-CoV2 infection * Medical Research Council (MRC) dyspnea score ≥ 2 (MRC 2= short of breath when hurrying on the level or walking up a slight hill * Availability to a computer, tablet, or smart phone with internet access * Able to provide informed consent. Exclusion Criteria: * Breathlessness of unknown cause * Primary diagnosis of chronic hyperventilation syndrome * Currently participating in a rehabilitation programme e.g.,pulmonary/cardiac rehabilitation (patients that have completed PR \>4-weeks will be eligible).
Conditions Hypertension
Phase NA
Enrollment 500
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Emergency department visits provide an opportunity to identify people with undiagnosed, untreated, or uncontrolled high blood pressure. In Reach Out, we will test whether a mobile health intervention yields a greater reduction in blood pressure than usual care among individuals identified with high blood pressure during a safety-net emergency department visit. Subsequently, we will estimate the reduction in heart attack, stroke, and dementia if Reach Out were implemented across all U.S. safety-net emergency departments.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Behavioral: Self-Measured Blood Pressure Monitoring — Prompted SMBP with tailored feedback
  • Behavioral: Physician appointment and transportation scheduling — Physician appointment and transportation scheduling or none dependent on current BP control

Primary Outcomes

  • Change in systolic blood pressure (6 month)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-07-22
Completion: 2028-11-30
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 500 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Northwestern University
Collaborators: University of Michigan, Ohio State University
Contact Information
Study Contact:
Lesli Skolarus, MD, MS
312-503-0644
lesli.skolarus@northwestern.edu
William Meurer, MD
Rockefeller Oteng, MD
Hurley Medical Center
Interventions
  • Behavioral: Self-Measured Blood Pressure Monitoring — Prompted SMBP with tailored feedback
  • Behavioral: Physician appointment and transportation scheduling — Physician appointment and transportation scheduling or none dependent on current BP control
Study Locations (1 sites)
Hurley Medical Center, Flint, Michigan 48503 United States
Eligibility Criteria
While in the ED, the patient must meet all of the following: * Adult (≥18 y/o) * At least one BP with Systolic BP ≥160 or a Diastolic BP ≥100 (criteria 1) * If the patient has repeated measurements after achieving Criteria 1, at least one of the repeat BP remains systolic BP ≥140 or a diastolic BP ≥90 * Must have cell phones with text-messaging capability * Likely to be discharged from the ED Exclusion Criteria for Main Trial Participants: * Critical illness * Unable to read English (\<1% at study site) * Incarcerated * Pregnant * Pre-existing condition making 6-month follow-up unlikely
Conditions Breast Cancer, Organoids
Phase Not Applicable
Enrollment 306
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Development of tools to predict patients chemo-sensitivity and identification of corresponding biomarkers is an urgent challenge for BC patients lacking targeted therapies, such as TNBC, or for patients experiencing relapse after adjuvant chemotherapy or targeted therapies. The refinement of 3D-cultivation techniques, experienced in the last decade, has allowed cultivation of patients-derived cancer cells in organotypic structures, named patient-derived organoids (PDO), which preserve histologic, genomic and transcriptomic features of primary tumors. PDO allow propagation, pharmacological treatment and genetic manipulation of patients-derived cancer cells in a close to physiology setting, thus representing a promising tool in the development of personalized therapies

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Primary Outcomes

  • evaluate the histological and molecular conformity (yes/no) between PDO and matched primary and/or recurrent BC sample, in order to develop a live biobank of ER/PR+, HER2+ and TNBC PDO. (36 months)
  • evaluate the sensitivity of ER/PR+, HER2+ and TNBC PDO to novel therapeutic agents in clinical trials for BC or other cancer types (42 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2023-06-15
Completion: 2027-06-15
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 306 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Contact Information
Study Contact:
Alba Di Leone, Doc
0039 3474980503
alba.dileone@policlinicogemelli.it
Chiara Naro, Doc
0039 3495087203
chiara.naro@unicatt.it
alba di leone, MD
0039 3474980503
alba.dileone@policlinicogemelli.it
IRCCS Fondazione Policlinico A. Gemelli
Interventions
N/A
Study Locations (1 sites)
IRCCS Fondazione Policlinico A. Gemelli, Roma, 00168 Italy
Eligibility Criteria
Inclusion Criteria: * women diagnosed with primary BC, eligible for surgical resection of the tumor according to national and international guidelines. age between 18 and 70 years; newly diagnosed breast neoplasms, tumor size of at least 1.5 cm diameter. Exclusion Criteria: breast cancer diagnosed during pregnancy, neoadiuvant chemotherapy